Intas Pharma bags CDSCO panel nod to study Human Normal Immunoglobulin - Video
|
Overview
Pharmaceutical major Intas Pharma has got the go-head from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct the Phase III Clinical Trial of immunizing agent Human Normal Immunoglobulin for Intravenous Administration IP/EP, 5% and 10% Solution.
However, the permission is conditional upon the submission of a principal investigator (PI) undertaking and the requirement that the clinical trial sites be geographically dispersed
For more details, check out the full story on the link below:
Intas Pharma Gets CDSCO Panel Okay To Study Human Normal Immunoglobulin
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
